Berlin - Delayed Quote EUR

PreveCeutical Medical Inc (18H.BE)

0.0170

0.0000

(0.00%)

At close: April 23 at 7:31:03 PM GMT+2

PreveCeutical Announces Up-Sized Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that, further to its news release dated April 2, 2025, that the Company will be increasing the size of its previously announced non- brokered private placement (the "Offering") from $500,000 to $700,000, resulting in up to 23,333,333 units (each, a "Unit") of the Company at a price of $0.03 per Unit. ...

Newsfile 9 days ago

PRVCF
PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 16,666,667 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $500,000. Each Unit consists of one (1) common share of the Company (each, a "Share") ...

Newsfile 21 days ago

PRVCF
PreveCeutical Announces Update to Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its news release dated January 24, 2025, the Company has received an extension from The CSE (the "CSE") to close its non-brokered private placement of up to 10,000,000 units of the Company (the "Units") at a price of CDN$0.03c per Unit for aggregate gross proceeds of up to ...

Newsfile last month

PRVCF
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology.PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scienti

Newsfile 2 months ago

PRVCF
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects

Vancouver, British Columbia--(Newsfile Corp. - February 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical") a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products is pleased to announce that is has appointed Dr. Bryan Jones ("Bryan") as an advisor to the Company as Director of Sol-Gel Special Projects effective 31 January, 2025.Bryan Jones brings o

Newsfile 2 months ago

PRVCF
PreveCeutical Announces Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 10,000,000 units in the capital of the Company (the "Units") at a price of $0.03 per Unit for gross proceeds of up to $300,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and ...

Newsfile 2 months ago

PRVCF
BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. today announced its participation in the upcoming 43rd JP Morgan Healthcare Conference, taking place Janu

Newsfile 3 months ago

PRVCF
PreveCeutical Announces Change of Auditors

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024.PreveCeutical's board of directors accepted the resignation of the Former Auditor and appointed the Succes

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Patroski J. Lawson as an independent director effective on 6 December, 2024.Stephen Van Dev

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Barry Ticho M.D. Ph.D to the Scientific Advisory Board effective on 1 December, 2024.S

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 1 December, 2024.Stephen Van Deventer, CEO of BioGe

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed as an independent director effective on 30 November, 2024.Stephen Van Deventer, CEO of BioG

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Deepak Sampath as an independent director effective on 21 November, 2024.Stephen Van D

Newsfile 4 months ago

PRVCF
BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela Dellbegovic, FRSE to the Scientific Advisory Board effective on 19 November,

Newsfile 4 months ago

PRVCF
PreveCeutical's Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. announce the appointments of Dr. Linnea Olofsson as Chief Scientific Officer (CSO) and Dr. Harry Parekh

Newsfile 5 months ago

PRVCF
PreveCeutical Announces Closing of BioGene Therapeutics Transaction

Vancouver, British Columbia--(Newsfile Corp. - November 15, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that, further to its news release dated October 30, 2024, PreveCeutical has closed the intellectual property asset sale transaction ("Transaction") among its affi

Newsfile 5 months ago

PRVCF
PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly-owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Mariya Georgieva as President effective on 11 November, 2024.Stephen Van Deventer, Cha

Newsfile 5 months ago

PRVCF
PreveCeutical Launches Strategic Partnership with BioGene Therapeutics

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has signed a definitive agreement on the 29 October, 2024 (the "Agreement") to sell certain intellectual property assets (the "Assets") owned by itself and

Newsfile 5 months ago

PRVCF
PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services

Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has engaged Toronto-based Phoenix Corporate Finance Inc. ("Phoenix") as its advisory firm to provide strategic and corporate advisory services relating to

Newsfile 6 months ago

PRVCF
PreveCeutical Engages Outside The Box Capital Inc. to Provide Marketing Services

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a Marketing Service Agreement dated effective September 1, 2024 (the "Agreement") with Outside the Box Capital Ltd. ("OTB"), whereby OTB will provide the Company with certain marketing services (the "Services").As consideration for the Services, the Company will pay OTB a cash fee in the aggrega

Newsfile 7 months ago

PRVCF

Performance Overview

Return	18H.BE	S&P/TSX Composite index (^GSPTSE)
YTD	-10.53%	-0.60%
1-Year	-10.53%	+11.18%
3-Year	-15.84%	+15.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PreveCeutical Medical Inc (18H.BE)

PreveCeutical Announces Up-Sized Non-Brokered Private Placement

PreveCeutical Announces Update to Non-Brokered Private Placement

PreveCeutical Announces Update to Private Placement

PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease

Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects

PreveCeutical Announces Non-Brokered Private Placement

BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference

PreveCeutical Announces Change of Auditors

BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors

BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho

BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board

BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors

BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors

BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board

PreveCeutical's Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer

PreveCeutical Announces Closing of BioGene Therapeutics Transaction

PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President

PreveCeutical Launches Strategic Partnership with BioGene Therapeutics

PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services

PreveCeutical Engages Outside The Box Capital Inc. to Provide Marketing Services

Performance Overview